HUTCHMED Operating Margin from 2010 to 2026

HCM Stock  USD 14.57  0.21  1.42%   
HUTCHMED DRC Operating Profit Margin yearly trend continues to be very stable with very little volatility. Operating Profit Margin is likely to drop to -0.08.
Check HUTCHMED DRC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HUTCHMED DRC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.9 M, Interest Expense of 3.5 M or Selling And Marketing Expenses of 32.3 M, as well as many indicators such as Price To Sales Ratio of 4.33, Dividend Yield of 0.0024 or PTB Ratio of 3.59. HUTCHMED financial statements analysis is a perfect complement when working with HUTCHMED DRC Valuation or Volatility modules.
  
Build AI portfolio with HUTCHMED Stock
Check out the analysis of HUTCHMED DRC Correlation against competitors.
To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.
Evaluating HUTCHMED DRC's Operating Margin across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into HUTCHMED DRC's fundamental strength.

Latest HUTCHMED DRC's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of HUTCHMED DRC over the last few years. It is HUTCHMED DRC's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HUTCHMED DRC's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (0.01) %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

HUTCHMED Operating Margin Regression Statistics

Arithmetic Mean(0.25)
Geometric Mean0.16
Coefficient Of Variation(151.38)
Mean Deviation0.31
Median(0.08)
Standard Deviation0.38
Sample Variance0.15
Range1.2075
R-Value(0.34)
Mean Square Error0.14
R-Squared0.12
Significance0.18
Slope(0.03)
Total Sum of Squares2.33

HUTCHMED Operating Margin History

2026 -0.0778
2025 -0.0741
2024 -0.0644
2023 0.0219
2022 -0.96
2021 -0.92
2020 -0.86

About HUTCHMED DRC Financial Statements

HUTCHMED DRC investors utilize fundamental indicators, such as Operating Margin, to predict how HUTCHMED Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchmed China operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 2110 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether HUTCHMED DRC is a strong investment it is important to analyze HUTCHMED DRC's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact HUTCHMED DRC's future performance. For an informed investment choice regarding HUTCHMED Stock, refer to the following important reports:
Check out the analysis of HUTCHMED DRC Correlation against competitors.
To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Will Pharmaceuticals sector continue expanding? Could HUTCHMED diversify its offerings? Factors like these will boost the valuation of HUTCHMED DRC. Market participants price HUTCHMED higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every HUTCHMED DRC data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
16.333
Earnings Share
2.65
Revenue Per Share
3.52
Quarterly Revenue Growth
(0.09)
Return On Assets
(0.01)
Understanding HUTCHMED DRC requires distinguishing between market price and book value, where the latter reflects HUTCHMED's accounting equity. The concept of intrinsic value - what HUTCHMED DRC's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push HUTCHMED DRC's price substantially above or below its fundamental value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, HUTCHMED DRC's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.